

IRISH JOURNAL OF PSYCHOLOGICAL MEDICINE

VOL 14 NO 3 SEPTEMBER 1997

ISSN 0790-9667



Prescribing Information: XANAX

Presentation: White, oval, biconvex tablet containing 250 micrograms (0.25mg) alprazolam, scored on one side and marked 'UPJOHN 29' on the other. Pink, oval, biconvex tablet containing 500 micrograms (0.5mg) alprazolam, scored on one side and marked 'UPJOHN 55' on the other. Lavender, oval, biconvex tablet containing 1mg alprazolam, scored on one side and marked 'UPJOHN 90' on the other. **Uses:** Xanax is indicated for the treatment of anxiety neuroses, reactive (neurotic) depression, and mixed anxiety depression, also any of the foregoing associated with other diseases such as the chronic phase of alcohol withdrawal. Xanax is also effective for the blocking or attenuation of panic attacks in patients with and without phobic avoidance. **Dosage and administration:** Adults only. Optimum dosage of Xanax is based upon the severity of the symptoms and the individual patient response.

Anxiety - 0.25mg to 0.5mg three times daily, increasing if required to a total of 3mg daily. **Reactive Neurotic Depression:** 0.5mg three times daily increasing if required to a total of 4mg daily. **Geriatric Patients or in the presence of debilitating disease:** 0.25mg two to three times daily to be gradually increased if needed and tolerated. **Panic related disorders:** 0.5 mg to 1 mg given at bedtime. Dosage adjustments should be in increments no greater than 1 mg every three to four days. Additional doses can be added until a t.i.d. or q.i.d. schedule is achieved. **Contra-indications:** Hypersensitivity to benzodiazepines. **Precautions:** May cause drowsiness. Pregnancy and lactation. Concurrent use of CNS depressants should be avoided. The dosage of Xanax should be terminated gradually as abrupt termination may be associated with withdrawal effects. **Side effects:** Mild and transitory. Drowsiness and lightheadedness. Rarely blurred vision, headache, depression, insomnia and gastrointestinal symptoms. **Pharmaceutical precautions:** Protect from light. **GMS price:** 0.25mg x 100 tabs, £5.02, 0.5mg x 100 tabs, £9.65, 1.0mg x 100 tabs, £20.13.

Product Authorisation Numbers: 0.25mg x 100 PA 16/37/1, 0.5mg x 100 PA 16/37/2, 1.0mg x 100 PA 16/37/3. **PA Holder:** Upjohn LTD, Davy Avenue, Knowhill Milton Keynes, MK5 8PH. Distributed in Ireland by Pharmacia & Upjohn, Airways Industrial Estate, Cloghran, Dublin 17.

Further information is available on request from Pharmacia & Upjohn, Airways Industrial Estate, Cloghran, Dublin 17. June 1996. Legal Category: SIA.

Pharmacia & Upjohn

PO Box 1752, Airways Industrial Estate, Dublin 17, Ireland
Telephone Nat 01 842 8733
Int +353 1 8428733
Facsimile Nat 01 842 8936
Int +353 1 842 8936

Registered in Ireland No. 168602

<https://doi.org/10.1017/S0790966700003128> Published online by Cambridge University Press

Xan1/AB/896

The mundane can seem extraordinary when viewed differently, as in the above Scanning Electron Micrograph (130 x enlargement) of an insect's head

Helps them regain perspective - Quickly


© 1996 Pharmacia & Upjohn

TM

© 1996 Pharmacia & Upjohn

© 1996 Pharmacia & Upjohn

In Anxiety and Panic Disorders...



Helps them regain perspective - Quickly

The mundane can seem extraordinary when viewed differently, as in the above Scanning Electron Micrograph (130 x enlargement) of an insect's head

Editor-in-Chief: Brian Lawlor**Editorial Assistant:** Niamh Gleeson**Advertising Manager:**

Mary Kate O'Flanagan

Founding Editor: Mark Hartman**Editors:** Timothy Dinan (London),
David King (Belfast)**Deputy Editor:** Brian O'Shea (Dublin)**Associate Editors:** Ken Brown (Belfast), Patricia Casey (Dublin), Anthony Clare (Dublin), Stephen Cooper (Belfast), Thomas Fahy (Galway), Michael Fitzgerald (Dublin), Michael Kelleher (Cork), Brian Leonard (Galway), Roy McClelland (Belfast), Aidan McGennis (Dublin), Ciaran O'Boyle (Dublin), Eadbhard O'Callaghan (Dublin), Art O'Connor (Dublin), Ethna O'Gorman (Belfast), Ian Pullen (Edinburgh), David Sheehan (Tampa), Philip Snaith (Leeds), Hugh Staunton (Dublin), John Waddington (Dublin), Richard Williams (Calgary)**Statistical Editor:** Leslie Daly (Dublin)**Deputy Statistical Editor:**

Ronan Conroy (Dublin)

Submissions & correspondence to:The Editor,
Irish Journal of Psychological Medicine,
99 Upper George's Street,
Dun Laoghaire,
Co Dublin.**Telephone**

01-2803967; Int: +353-1-2803967

Fax

01-2807076; Int: +353-1-2807076

PublisherMedMedia Ltd.
Media House,
99 Upper George's Street,
Dun Laoghaire,
Co Dublin.**Printings:** New Cityview Press**Subscriptions**Rates per volume of four issues
(Mar, Jun, Sept, Dec)
STG£43 EU, us\$96 USA, STG£53
elsewhere (single issues us\$28 USA,
STG£13.25 elsewhere) incl. airmail
postage internationally.**Subscription enquiries, orders
and cheques made payable to:**Royal Society of Medicine Press Ltd.,
1 Wimpole St,
London, W1M 8AE, UK.
Tel: 0171-2902927;
int: +44-171-2902927.
Fax: 0171-2902929;
int: +44-171-2902929.**Circulation**

3,000 to 54 countries.

Journal participates in the World Health
Organisation project to improve
distribution of scientific materials on
mental health.Publication does not imply
endorsement. Limited photocopying
authorisation granted for a fee to
Copyright Clearance Center,
27 Congress Street, Salem, MA 01970,
USA, or to appropriate Reproduction
Rights Organisation; isolated non-profit,
academic photocopying excepted.**EDITORIAL****83 Evidence-based medicine and psychiatry**

John Geddes

ORIGINAL PAPERS**85 Clozapine plasma levels and dosing strategies in patients with treatment-refractory schizophrenia**

Peter Buckley, Philip Cola, Mitsuru Hasegawa, Christine Lys & Paul Thompson

88 Detection of personality disorders by a community mental health team: a study of diagnostic accuracy

Angela Hassiotis, Peter Tyrer & Domenic Cicchetti

92 Community and hospital residential care: a comparative evaluation

Deborah Cullen, Jerome Carson, Frank Holloway, Aisling Towey, Angela Jumbo, Norma Smellie & Tony Glynn

BRIEF REPORTS**99 Diogenes' syndrome - a load of old rubbish?**

Lynne M Drummond, Joanne Turner & Steven Reid

102 General practitioners' opinion of a new psychiatry of old age service

Margaret Kelleher

AUDITS**105 Where to? A survey of the residual population of a district mental hospital and their predicted placement needs**

Ciaran Smyth, Angela Mohan, Con Buckley, Anna Clarke

108 A survey of psychotropic drug use in elderly psychiatric inpatients

Ruth Loane, Sheila McGauran, Con Buckley, Fenton Howell, Zachary Johnson & Angela Mohan

PERSPECTIVE**112 Chaos theory, psychiatry, and a quiet revolution**

John Tobin

CASE REPORT**115 Diogenes' syndrome: review and case history**

Brian O'Shea & Jane Falvey

84 Guidelines for authors**105a John Dunne Medal****117 Letters to the Editor****Cover illustration:** 'The Lustre Jug', Walter Osbourne (1859-1903)

Indexed and abstracted by BIOLOGICAL ABSTRACTS (BIOSIS Previews); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE/INIST; PASCAL; EXCERPTA MEDICA/EMBASE; INSTITUTE FOR SCIENTIFIC INFORMATION; CURRENT CONTENTS/Social & Behavioural Sciences (Social Science CITATION INDEX, Research Alert); PSYCHOLOGICAL ABSTRACTS (PsycINFO/PsycLIT); Cumulative Index to Nursing & Allied Health Literature, Current AIDS Literature (CAB Abstracts), International Pharmaceutical Abstracts, Linguistics & Language Behaviour Abstracts, Nutrition Abstracts and Reviews, (CAB Abstracts), Referativnyi Zhurnal, Social Planning/Policy & Development Abstracts, Social Work Research & Abstracts, Sociological Abstracts.

Microfilm, microfiche & article copies from University Microfilms International, 300 North Zeeb Rd., Ann Arbor, MI 48106, USA. Journal included in the Adonis service, whereby article copies can be printed out from compact disks (CD-ROM) on demand; explanatory leaflet available from ADONIS BV, PO Box 639, 1000 AV Amsterdam, The Netherlands. Journal listed in Ulrich's International Periodicals Directory (Bowker International Serials Database), EBSCO's Selected Periodicals for the Medical and Health Sciences, & EBSCO's Librarians' Handbook.



Fast Response

Can start to improve symptoms within seven days

FIRST CHOICE
LUSTRAL™ 50mg
 sertraline

A first choice antidepressant



Abbreviated Prescribing Information:
LUSTRAL™ (sertraline)

Presentation: Tablets containing 50mg or 100mg sertraline. **Indications:** Treatment of symptoms of depressive illness, including accompanying symptoms of anxiety. Prevention of relapse or recurrence of depressive episodes, including accompanying symptoms of anxiety. Obsessive compulsive disorder (OCD). **Dosage:** Lustral should be given as a single daily dose. The initial dose is 50mg and the usual

antidepressant dose is 50mg. Dosage can be further increased, if appropriate, to a maximum of 200mg daily. Patients should be maintained on the lowest effective dose. **Use in children:** Not recommended. **Use in elderly:** Usual adult dose. **Contra-indications:** Hypersensitivity to this group of drugs. Hepatic insufficiency, unstable epilepsy and convulsant disorders, pregnancy and lactation. Do not use with, or within two weeks of ending treatment with

MAOIs. At least 14 days should elapse before starting any MAOI following discontinuation of Lustral. **Precautions, warnings:** Renal insufficiency, ECT, epilepsy, driving. Lustral should be discontinued in a patient who develops seizures. Lustral should not be administered with benzodiazepines or other tranquilizers in patients who drive or operate machinery. The patient should be monitored for signs of suicide or mania. **Drug Interactions:** Caution with other centrally active medication. Serotonergic drugs such as tryptophan or fenfluramine should not be used with Lustral. Lithium levels should be monitored. Although Lustral has been shown to have no adverse interaction with alcohol, concomitant use with alcohol is not recommended. The potential for Lustral to interact with other highly protein bound drugs should be borne in mind. Interactions with e.g. warfarin, diazepam, tolbutamide and cimetidine have not been fully assessed. With warfarin prothrombin time should be monitored when Lustral is initiated or stopped. **Side-Effects:** Dry mouth, nausea, diarrhoea, loose stools, ejaculatory delay, tremor,

increased sweating, dizziness, insomnia, somnolence, headache and dyspepsia. Rarely, abnormal LFTs, hyponatraemia. The following have been reported with Lustral but may have no casual relationship: movement disorders, convulsions, menstrual irregularities, hyperprolactinaemia, galactorrhoea and rash. As with other serotonin re-uptake inhibitors rare reports of agitation, confusion, depersonalisation, hallucinations, nervousness, postural hypotension, hypo/hypertension, tachycardia and arrhythmias. As with all psychoactive medicines, possible side effects on discontinuation, such as dizziness, sensory disturbance, sleep disturbance, agitation or anxiety, nausea and sweating. **Legal Category:** S1A. **Package Quantities:** 50mg tablet (PA 822/1/4) Calendar pack of 28; 100mg tablet (PA 822/1/5) Calendar pack of 28. **Product Authorisation Holder:** Pfizer (Ireland) Limited, Pharmapark, Chapelizod, Dublin 20, Republic of Ireland. **Further information on request:** Pfizer (Ireland) Limited. Date last revised: 1/11/96 66973 June 97

